

Oesophagus diseases

Karthik Ravi

UEG Week Vienna 2024

Presentation

Endoscopy

Gut Microbiota

IBD

Oesophagus

Stomach & H. Pylori

October 13, 2024

The speaker reviewed DDW abstracts on oesophageal disorders, highlighting evidence that normal Flip can rule out significant motility abnormalities, TissueCipher SP9 may improve surveillance strategies for nondysplastic Barrett's oesophagus, neoplastic recurrence after endoscopic eradication therapy is uncommon, etrasimod showed promise in eosinophilic esophagitis, and vonoprazan demonstrated rapid and durable improvement in non-erosive reflux disease.

KEY POINTS

- In 558 patients who underwent manometry and Flip, the speaker reported that over 90% with a normal Flip had no significant motility abnormality, and 89% with obstruction and weak contractile response had conclusive EGJ outflow obstruction, supporting Flip as a screening tool and confirmatory test.
- In a 699-patient Barrett's oesophagus cohort, TissueCipher SP9 at index endoscopy improved appropriateness of surveillance recommendations compared to guidelines and real world care, the speaker stated, reducing under-treatment of patients who progressed and overuse of endoscopy in those who did not.
- Among 152 patients who achieved complete eradication of intestinal metaplasia after endoscopic eradication therapy, neoplastic recurrence was rare at 1.4 per 100 person-years over a mean 87-month follow-up, the speaker reported, with most recurrence within 13 months and all 13 recurrences successfully re-treated.
- In the phase 2 VOYAGE study of 108 eosinophilic esophagitis patients, etrasimod 2mg daily met the primary endpoint of decreased peak eosinophil count at 16 weeks and showed durable histologic, endoscopic, and symptomatic improvement to 52 weeks with no serious treatment-related adverse events, the speaker stated.

- In 772 patients with non-erosive reflux disease, vonoprazan 10 and 20mg daily met the primary endpoint of increased percentage of heartburn-free days at 4 weeks, with rapid onset as soon as 1 day and durable benefit such that over 75% of patients reported over 75% of days heartburn-free after 20 weeks, the speaker reported.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/92e6f6c8-9130-11ef-b245-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.